Evidence map›Paper›PMID 31783044›Full record

ArticleHuman pathology2020

MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative sequencing from different tumor areas.

Wei Chen, Rachel Pearlman, Heather Hampel, Colin C Pritchard, Michael Markow, Christina Arnold, Deborah Knight, Wendy L Frankel

Open access · greenAbstract readComparative Study
In one paragraph

Article in Human pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. International journal of ophthalmology · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Diagnostics of Mutations in MMR/Diagnostics (Basel, Switzerland) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Wei ChenDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210.
Rachel PearlmanDepartment of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210.
Heather HampelDepartment of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210.
Colin C PritchardDepartment of Laboratory Medicine, University of Washington, Seattle, Washington WA 98195.
Michael MarkowDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210.
Christina ArnoldDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210.
Deborah KnightDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210.
Wendy L FrankelDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210. Electronic address: Wendy.Frankel@osumc.edu.
The Ohio State University Wexner Medical Center · USUniversity of Washington · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

Mismatch repair protein (MMR) immunohistochemistry is an important tool in screening for Lynch syndrome in colorectal cancer patients. Unusual staining patterns such as heterogeneous MSH6 staining have been reported in colorectal and endometrial cancers. We aim to better understand MSH6 staining heterogeneity in colorectal cancer by comparative sequencing of different tumor areas for MMR and DNA polymerase mutations. Whole-section slides of 1754 colorectal cancers were reviewed for heterogeneous MSH6 staining, defined as discrete tumor areas with abrupt loss of staining juxtaposed to tumor areas with retained staining. Nine cases (0.05%) demonstrated heterogeneous MSH6 staining; none received neoadjuvant therapy prior to the specimen collection. The area of tumor with loss of MSH6 expression ranged from 5% to 60% (average 22%). Four cases had enough tissue remaining in both retained and lost MSH6 areas to perform tumor sequencing on both areas. All 9 cases were negative for MSH6 germline mutation; MSH6 heterogeneous staining was seen in tumors with MLH1 or PMS2 abnormalities (6 cases of MLH1 methylation, 2 PMS2 germline mutation, 1 MLH1 germline mutation). In addition, case 1 also had a somatic POLD1 exonuclease domain mutation (p.Y405C) in the MSH6 loss area but not in the intact area. We recommend reporting MSH6 heterogeneous pattern as MSH6 staining is present with a comment stating that the heterogeneous pattern typically does not indicate germline mutation in MSH6 but is commonly associated with abnormality in another MMR gene such as MLH1 or PMS2, or even other DNA repair genes such as DNA polymerase.

Indexed as

ImmunohistochemistryAgedAged, 80 and overBiomarkers, TumorColorectal NeoplasmsDNA-Binding ProteinsDNA MethylationDNA Mutational AnalysisDNA Polymerase IIIFemaleGenetic HeterogeneityGerm-Line MutationHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedBiomarkers, TumorDNA-Binding ProteinsDNA Polymerase IIIG-T mismatch-binding proteinMismatch Repair Endonuclease PMS2MLH1 protein, humanMutL Protein Homolog 1PMS2 protein, humanPOLD1 protein, humanc.3261Colorectal cancerDNA polymeraseHeterogeneous stainingMSH6 immunohistochemistry

Identifiers

PMID31783044
PMCPMC7191319
OpenAlexW2990278530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.